Global Benign Prostatic Hyperplasia Testing Market Size, Status and Forecast 2019-2025

1 Report Overview

• 1.1 Study Scope
• 1.2 Key Market Segments
• 1.3 Players Covered: Ranking by Benign Prostatic Hyperplasia Testing Revenue
• 1.4 Market by Type
  • 1.4.1 Global Benign Prostatic Hyperplasia Testing Market Size Growth Rate by Type: 2020 VS 2026
  • 1.4.2 Urinalysis
  • 1.4.3 Prostate-Specific Antigen (PSA) Blood Test
  • 1.4.4 Urodynamic Test
  • 1.4.5 Cystoscopy
• 1.5 Market by Application
  • 1.5.1 Global Benign Prostatic Hyperplasia Testing Market Share by Application: 2020 VS 2026
  • 1.5.2 Hospitals
  • 1.5.3 Diagnostic Centers
  • 1.5.4 Clinics
  • 1.5.5 Research Institutes
• 1.6 Study Objectives
• 1.7 Years Considered

2 Global Growth Trends

• 2.1 Global Benign Prostatic Hyperplasia Testing Market Perspective (2015-2026)
• 2.2 Global Benign Prostatic Hyperplasia Testing Growth Trends by Regions
  • 2.2.1 Benign Prostatic Hyperplasia Testing Market Size by Regions: 2015 VS 2020 VS 2026
  • 2.2.2 Benign Prostatic Hyperplasia Testing Historic Market Share by Regions (2015-2020)
  • 2.2.3 Benign Prostatic Hyperplasia Testing Forecasted Market Size by Regions (2021-2026)
• 2.3 Industry Trends and Growth Strategy
  • 2.3.1 Market Top Trends
  • 2.3.2 Market Drivers
  • 2.3.3 Market Challenges
  • 2.3.4 Porter’s Five Forces Analysis
  • 2.3.5 Benign Prostatic Hyperplasia Testing Market Growth Strategy
  • 2.3.6 Primary Interviews with Key Benign Prostatic Hyperplasia Testing Players (Opinion Leaders)

3 Competition Landscape by Key Players

• 3.1 Global Top Benign Prostatic Hyperplasia Testing Players by Market Size
  • 3.1.1 Global Top Benign Prostatic Hyperplasia Testing Players by Revenue (2015-2020)
  • 3.1.2 Global Benign Prostatic Hyperplasia Testing Revenue Market Share by Players (2015-2020)
  • 3.1.3 Global Benign Prostatic Hyperplasia Testing Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
• 3.2 Global Benign Prostatic Hyperplasia Testing Market Concentration Ratio
  • 3.2.1 Global Benign Prostatic Hyperplasia Testing Market Concentration Ratio (CR5 and HHI)
  • 3.2.2 Global Top 10 and Top 5 Companies by Benign Prostatic Hyperplasia Testing Revenue in 2019
• 3.3 Benign Prostatic Hyperplasia Testing Key Players Head office and Area Served
• 3.4 Key Players Benign Prostatic Hyperplasia Testing Product Solution and Service
• 3.5 Date of Enter into Benign Prostatic Hyperplasia Testing Market
• 3.6 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)

• 4.1 Global Benign Prostatic Hyperplasia Testing Historic Market Size by Type (2015-2020)
• 4.2 Global Benign Prostatic Hyperplasia Testing Forecasted Market Size by Type (2021-2026)

5 Market Size by Application (2015-2026)

• 5.1 Global Benign Prostatic Hyperplasia Testing Market Size by Application (2015-2020)
• 5.2 Global Benign Prostatic Hyperplasia Testing Forecasted Market Size by Application (2021-2026)

6 North America

• 6.1 North America Benign Prostatic Hyperplasia Testing Market Size (2015-2020)
• 6.2 Benign Prostatic Hyperplasia Testing Key Players in North America (2019-2020)
• 6.3 North America Benign Prostatic Hyperplasia Testing Market Size by Type (2015-2020)
• 6.4 North America Benign Prostatic Hyperplasia Testing Market Size by Application (2015-2020)

7 Europe

• 7.1 Europe Benign Prostatic Hyperplasia Testing Market Size (2015-2020)
• 7.2 Benign Prostatic Hyperplasia Testing Key Players in Europe (2019-2020)
• 7.3 Europe Benign Prostatic Hyperplasia Testing Market Size by Type (2015-2020)
• 7.4 Europe Benign Prostatic Hyperplasia Testing Market Size by Application (2015-2020)

8 China

• 8.1 China Benign Prostatic Hyperplasia Testing Market Size (2015-2020)
• 8.2 Benign Prostatic Hyperplasia Testing Key Players in China (2019-2020)
• 8.3 China Benign Prostatic Hyperplasia Testing Market Size by Type (2015-2020)
• 8.4 China Benign Prostatic Hyperplasia Testing Market Size by Application (2015-2020)

9 Japan

• 9.1 Japan Benign Prostatic Hyperplasia Testing Market Size (2015-2020)
• 9.2 Benign Prostatic Hyperplasia Testing Key Players in Japan (2019-2020)
• 9.3 Japan Benign Prostatic Hyperplasia Testing Market Size by Type (2015-2020)
• 9.4 Japan Benign Prostatic Hyperplasia Testing Market Size by Application (2015-2020)

10 Southeast Asia

• 10.1 Southeast Asia Benign Prostatic Hyperplasia Testing Market Size (2015-2020)
• 10.2 Benign Prostatic Hyperplasia Testing Key Players in Southeast Asia (2019-2020)
• 10.3 Southeast Asia Benign Prostatic Hyperplasia Testing Market Size by Type (2015-2020)
• 10.4 Southeast Asia Benign Prostatic Hyperplasia Testing Market Size by Application (2015-2020)

11 India

• 11.1 India Benign Prostatic Hyperplasia Testing Market Size (2015-2020)
• 11.2 Benign Prostatic Hyperplasia Testing Key Players in India (2019-2020)
• 11.3 India Benign Prostatic Hyperplasia Testing Market Size by Type (2015-2020)
• 11.4 India Benign Prostatic Hyperplasia Testing Market Size by Application (2015-2020)

12 Central & South America

• 12.1 Central & South America Benign Prostatic Hyperplasia Testing Market Size (2015-2020)
• 12.2 Benign Prostatic Hyperplasia Testing Key Players in Central & South America (2019-2020)
• 12.3 Central & South America Benign Prostatic Hyperplasia Testing Market Size by Type (2015-2020)
• 12.4 Central & South America Benign Prostatic Hyperplasia Testing Market Size by Application (2015-2020)

13 Key Players Profiles

• 13.1 AEternaZentaris
  • 13.1.1 AEternaZentaris Company Details
  • 13.1.2 AEternaZentaris Business Overview
  • 13.1.3 AEternaZentaris Benign Prostatic Hyperplasia Testing Introduction
  • 13.1.4 AEternaZentaris Revenue in Benign Prostatic Hyperplasia Testing Business (2015-2020))
  • 13.1.5 AEternaZentaris Recent Development
• 13.2 Astellas Pharma
  • 13.2.1 Astellas Pharma Company Details
  • 13.2.2 Astellas Pharma Business Overview
  • 13.2.3 Astellas Pharma Benign Prostatic Hyperplasia Testing Introduction
  • 13.2.4 Astellas Pharma Revenue in Benign Prostatic Hyperplasia Testing Business (2015-2020)
  • 13.2.5 Astellas Pharma Recent Development
• 13.3 Eli Lilly and Company
  • 13.3.1 Eli Lilly and Company Company Details
  • 13.3.2 Eli Lilly and Company Business Overview
  • 13.3.3 Eli Lilly and Company Benign Prostatic Hyperplasia Testing Introduction
  • 13.3.4 Eli Lilly and Company Revenue in Benign Prostatic Hyperplasia Testing Business (2015-2020)
  • 13.3.5 Eli Lilly and Company Recent Development
• 13.4 IntelGenx Technologies Corp
  • 13.4.1 IntelGenx Technologies Corp Company Details
  • 13.4.2 IntelGenx Technologies Corp Business Overview
  • 13.4.3 IntelGenx Technologies Corp Benign Prostatic Hyperplasia Testing Introduction
  • 13.4.4 IntelGenx Technologies Corp Revenue in Benign Prostatic Hyperplasia Testing Business (2015-2020)
  • 13.4.5 IntelGenx Technologies Corp Recent Development
• 13.5 Nymox Pharmaceutical Corporation
  • 13.5.1 Nymox Pharmaceutical Corporation Company Details
  • 13.5.2 Nymox Pharmaceutical Corporation Business Overview
  • 13.5.3 Nymox Pharmaceutical Corporation Benign Prostatic Hyperplasia Testing Introduction
  • 13.5.4 Nymox Pharmaceutical Corporation Revenue in Benign Prostatic Hyperplasia Testing Business (2015-2020)
  • 13.5.5 Nymox Pharmaceutical Corporation Recent Development
• 13.6 Protox Therapeutics
  • 13.6.1 Protox Therapeutics Company Details
  • 13.6.2 Protox Therapeutics Business Overview
  • 13.6.3 Protox Therapeutics Benign Prostatic Hyperplasia Testing Introduction
  • 13.6.4 Protox Therapeutics Revenue in Benign Prostatic Hyperplasia Testing Business (2015-2020)
  • 13.6.5 Protox Therapeutics Recent Development
• 13.7 Quest PharmaTech
  • 13.7.1 Quest PharmaTech Company Details
  • 13.7.2 Quest PharmaTech Business Overview
  • 13.7.3 Quest PharmaTech Benign Prostatic Hyperplasia Testing Introduction
  • 13.7.4 Quest PharmaTech Revenue in Benign Prostatic Hyperplasia Testing Business (2015-2020)
  • 13.7.5 Quest PharmaTech Recent Development

14 Analyst's Viewpoints/Conclusions

15 Appendix

• 15.1 Research Methodology
  • 15.1.1 Methodology/Research Approach
  • 15.1.2 Data Source
• 15.2 Disclaimer